Drug Profile
MSI 1953
Latest Information Update: 08 Aug 2007
Price :
$50
*
At a glance
- Originator Genaera Corporation
- Class Small molecules
- Mechanism of Action Mucin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lung disorders
Most Recent Events
- 05 Jan 2004 No development reported - Preclinical for Lung disorders in USA (unspecified route)
- 31 Dec 2000 Preclinical development for Lung disorders in USA (Unknown route)